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Abstract The recent advances in understanding the path-
ophysiology of focal segmental glomerulosclerosis (FSGS)
and molecular function of glomerular filtration barrier come
directly from genetic linkage and positional cloning studies.
The exact role and function of the newly discovered genes
and proteins are being investigated by in vitro and in vivo
mechanistic studies. Those genes and proteins interactions
seem to change susceptibility to kidney disease progression.
Better understanding of their exact role in the development
of FSGS may influence future therapies and outcomes in
this complex disease.
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Introduction
Focal segmental glomerulosclerosis (FSGS) is not a single
disease, as initially thought [1], but the histological
expression of a variety of distinct conditions [2]. It is a
clinically and genetically heterogeneous entity characterized
by a common renal biopsy picture of segmental scarring of
the glomerular capillary tuft affecting one or more glomer-
uli. Immunoglobulin (Ig)M and complement C3 may be
present in mesangium, attributed to macromolecular trap-
ping, but other immune deposits are absent. Hyaline
deposits may occupy capillary loops, initially in a sub-
endothelial location. In general, FSGS can be divided into
three etiologic categories: idiopathic, genetic, and reactive
(the latter including postadaptive and medication-associated
forms). Although the abnormalities of glomerular filtration
barrier have been implicated in the pathophysiology of
nephrotic syndrome for the last 30–40 years, it was only
during the last decade when genetic linkage studies coupled
with positional cloning uncovered new genes and their
products that were causally linked to human nephrotic
syndrome. Identifying expression abnormalities of those
genes contributed to the understanding of the pathophysiol-
ogy of FSGS in recent years.
Understanding the genetics of FSGS begins with ap-
preciating the molecular composition of glomerular filtra-
tion barrier comprised of podocytes, basement membrane
(GBM), and fenestrated endothelium. This barrier separates
blood from the urinary space and under physiologic
conditions selectively permits the ultrafiltration of solutes
and preventing the excessive leakage of large molecules,
such as albumin and clotting factors, with a molecular
weight greater than 40 kDa [3]. The glomerular filtration
barrier becomes incompetent and “leaky” in the case of
nephrotic syndrome, including FSGS. Under physiologic
conditions, podocytes are terminally differentiated epitheli-
al cells with a cell body and several foot processes that are
in contact with each other through the interpodocyte
connection, called slit diaphragm (SD). All of the genetic
defects identified to date affect gene transcription or
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e-mail: rworonie@aecom.yu.eduassembly of critical podocyte functional structures, includ-
ing SD, actin-based cytoskeleton, and adhesion complexes.
These genes include nephrin (NPHS1), podocin (NPHS2),
alpha-actinin-4 (ACTN-4), CD2-associated protein
(CD2AP), Wilm’s tumor gene (WT1), and transient receptor
potential cation 6 (TRPC6) (Table 1). Recently, mutations
in phospholipase epsilon C have been identified as a cause
of steroid-sensitive nephrotic syndrome [4]. It is still not
understood why the FSGS lesion is focal (only some
glomeruli are affected) and segmental (only part of the
glomerulus has the anatomic lesion).
Nephrin (NPHS1)
The NPHS1 gene mutations cause congenital nephrotic
syndrome of the Finnish type, an autosomal recessive
disorder characterized by massive proteinuria in utero and
nephrosis at birth. Although this disease is not pathologi-
cally characterized by FSGS, it was the first mutation of
structural protein of podocyte causally linked to nephrotic
syndrome [5]. Moreover, nephrin deficiency was detected
in other forms of nephrotic syndrome, and an overlap in the
genes encoding nephrin/podocin (NPHS1/NPHS2) mutation
spectrum (a triallelic hit) has recently been documented in
patients with congenital FSGS [6]. NPHS1 product nephrin
has 1,241 amino acid residues and belongs to the
immunoglobulin (Ig) family of cell adhesion molecules. It
contains a transmembrane domain, eight Ig-like repeats,
and one fibronectin III-like module. Nephrin was localized
by immunogold labeling and electron tomography at the slit
between podocyte foot processes in a network of 35-nm
long, globular cross-strands lining lateral, elongated pores
in a zipper-like model [7]. Those pores are the same as or
smaller than albumin molecules. Patients with NPHS1
mutations and nephrin-knockout mice had only narrow
filtration slits that lacked the slit diaphragm network and
the 35-nm-long strands; these findings suggest that nephrin
molecules are directly involved in constituting the macro-
molecule-retaining slit diaphragm and its pores [8]. Func-
tionally, nephrin controls the podocyte cytoskeleton in vivo
by interacting with other proteins, such as Src homology-2
(SH2)/SH3 domain-containing Nck adaptor proteins [7].
Originally described mutation in Finnish patients was a
two-nucleotide deletion in exon 2 [5], but other mutations
have been reported since. Those include deletions, inser-
tions, nonsense, missense, splicing mutations, and common
polymorphisms [9–11].
Podocin (NPHS2)
Positional cloning identified NPHS2, encoding podocin, as
a causative gene in autosomal recessive steroid-resistant
nephrotic syndrome, including FSGS [12]. NPHS2 encodes
a putative 383 amino acid protein of approximately 42 kDa.
It belongs to the stomatin family proteins (band-7 proteins).
NPHS2 expression is restricted to the podocytes, as shown
by in situ hybridization studies, and the protein is an
integral plasma membrane protein associated with special-
Table 1 Gene mutations that are causally linked to focal segmental glomerulosclerosis (FSGS)
Gene
symbol
Gene locus Protein Mode of inheritance Renal manifestations Extrarenal manifestations
NPHS2 1q25.31 Podocin Autosomal recessive Minimal change
nephropathy, FSGS
None
ACTN4 19q13 Alpha-actinin-4 Autosomal dominant FSGS None
TRPC6 11q21.22 Transient receptor
potential cation channel
6
Autosomal dominant FSGS None
PLCE1 10q23.24 Phospholipase C epsilon Autosomal recessive Diffuse mesangial
sclerosis and FSGS
None
WT1 11p13 Wilm’s tumor
suppressor protein
Autosomal dominant,
de novo mutation
Diffuse mesangial
sclerosis and FSGS
Genitourinary abnormalities
LMXB1 9q34.1 Lim homeobox
transcription factor 1β
Autosomal dominant FSGS Dystrophic nails, absent or
malformed patella
tRNA
Leu Mitochondrial
genome
NA Maternal FSGS,
tubulointerstitial
nephritis
Muscle and brain disease, lactic
acidosis, deafness, diabetes mellitus
COQ2 4q21.22 Coenzyme Q2 homolog,
prenyltransferase
Autosomal recessive FSGS Neurologic and muscle abnormalities
ITGB4 17q25.1 Integrin β4 Autosomal recessive FSGS Epidermolysis bullosa
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the recruitment of nephrin into lipid rafts; it interacts with
nephrin and CD2AP [13] and facilitates nephrin signaling
[14]. In podocin-null mice, nephrin expression is increased,
whereas ZO1 (tight junction protein) and CD2AP expres-
sion is decreased. The mice die a few days after birth from
renal failure caused by diffuse mesangial sclerosis, and they
develop proteinuria during the antenatal period [15].
At present, at least 26 different NPHS2 mutations
associated with FSGS have been described, with a mutation
defined as a polymorphism that is present in homozygosity
in at least one patient with FSGS [12, 16–20]. Many
patients are compound heterozygotes with two distinct
mutations. The age of onset is generally in infancy or
childhood, but a few cases of adult onset kidney disease
have been described, with the oldest patient presenting at
age 36. In populations of European ancestry, NPHS2
mutations are present in 26% of families with familial
FSGS and 12–19% of sporadic pediatric FSGS [16, 18]. On
the other hand, NPHS2 mutations associated with pediatric
FSGS appear to be uncommon in children of Asian
ancestry [21]; little is known about children of African
ancestry. FSGS associated with NPHS2 mutations is
uniformly steroid resistant and generally shows poor
response to cyclosporine as well [18]. Although early
reports suggested otherwise, the consensus is now that
patients with NPHS2 mutations are at reduced risk for
recurrent FSGS following renal transplant [18, 22]. The
most common polymorphism is R229Q, with a heterozy-
gote frequency in the general population ranging from 0.03
to 0.13 [23]. R229Q heterozygosity has been associated
with microalbuminuria in a Brazilian population [24] and a
modest increased risk for FSGS in individuals of European
ancestry, but not individuals of African ancestry [23].
CD2-associated protein (CD2AP)
CD2-associated protein was discovered as a binding ligand
to the adhesion molecule CD2 during cell–cell interaction
of lymphocyte T with antigen presenting cell. This
interaction initiates the process of protein segregation,
CD2 clustering, and cytoskeletal polarization. The CD2AP
gene encodes a protein of 639 amino acids with a deduced
molecular mass of approximately 70 kDa, and messenger
ribonucleic acid (mRNA) is ubiquitously expressed in
human tissues. Cd2ap knock-out mice manifest compro-
mised immune function and they developed proteinuria by
2 weeks of age and died from renal failure at 6–7 weeks of
age [25]. In the kidney, the lesion resembles FSGS, with
mesangial cell hyperplasia and extracellular matrix deposi-
tion. Mice with Cd2ap haploinsufficiency (heterozygous
deletion) develop glomerular changes at 9 months of age.
They have increased susceptibility to glomerular injury by
immune complexes, with likely impairment of the intracel-
lular degradation pathways [26]. CD2AP is the human
ortholog of mouse Cd2ap, with 86% identity at the amino
acid level. CD2AP (originally named CMS) was identified
in the yeast two-hybrid system as interacting partner of
p130 (Cas), a cell cycle regulatory protein [27]. CD2AP is a
multifunctional adapter molecule, which is localized to the
cytoplasm, membrane ruffles, and leading edges of cells. It
functions as scaffolding protein involved in the dynamic
regulation of the actin cytoskeleton [27]. Two African
Americans with primary idiopathic FSGS were found to
have a mutation of CD2AP splice acceptor of exon 7 on one
allele. This mutation was not seen in control subjects.
Although these data are suggestive, family studies showing
a consistent relationship between mutation and renal
phenotype will be required to establish a pathogenic role.
Data supporting a role for CD2AP haploinsufficiency comes
from bigenic mouse models of FSGS involving pairwise
interaction of CD2AP, Fyn, and synaptopodin [28].
Alpha-actinin-4 (ACTN4)
ACTN4 mutations have been found to be the cause of
autosomal dominant FSGS in five families [29, 30]. These
patients tend to present in the teenage years or later and
progress to end-stage renal disease (ESRD) slowly. The
penetrance is variable, and some patients with mutations
have a very mild phenotype. Alpha-actinin-4 is an actin-
bundling protein associated with cytoskeleton, cell motility,
and cancer invasion [31]. It is highly expressed in
podocytes, and interacts with synaptopodin and with the
tight junction protein membrane-associated guanylate ki-
nase (MAGI)-1 in rat kidney epithelial cells [32]. Mutant
alpha-actinin-4 binds actin more tightly that does wild-type
alpha-actinin-4, indicating a gain of function mutation.
Actn4-null mice develop proteinuria, progressive glomeru-
lar disease, and die by several months of age. Histological
abnormalities are limited to the kidneys and include diffuse
podocyte foot process effacement and globally disrupted
morphology [33]. Cultured podocytes from these mice
adhere poorly to basement membrane components, suggest-
ing that podocyte loss may contribute to podocytopenia and
FSGS [34].
Transient receptor potential cation channel (TRPC6)
TRPC6 belongs to a protein family whose members
function as ion channels, mediating capacitative calcium
entry into the cell. TRPC6 is a nonselective calcium
channel that is activated by diacylglycerol in a membrane-
640 Pediatr Nephrol (2007) 22:638–644delimited fashion, independently of protein kinase C [35].
TRPC6 is responsible for calcium entry during cell
proliferation and is expressed primarily in the placenta,
lung, spleen, ovary, and small intestine. In the kidney,
TRPC6 is expressed in tubules and glomeruli, including
podoctyes and glomerular endothelial cells.
TRPC6 mutations have been identified in six families of
European and African geographic ancestry with autosomal
dominant FSGS [36, 37]. Each family carried a distinct
missense mutation. Age at renal disease presentation ranged
from 17 to 52 years, and the duration from onset to ESRD
averaged approximately 10 years. TRPC6 interacts with
nephrin and podocin, thus localizing the protein to the slit
diaphragm complex. Two mutant proteins are associated
with increased calcium amplitudes, indicating an activating
mutation. The discovery that abnormal TRPC6 disturbs
podocyte function suggests that calcium signaling may play
a critical role in facilitating podocyte regulation of
intracellular function, including control of cytoskeletal and
foot process architecture.
Phospholipase C epsilon 1 (PLCE1)
Recently, seven families with infantile or early onset
proteinuric renal disease were found to have mutations in
PLCE1, which encodes an isoform of phospholipase C, an
enzyme that participates in intracellular signaling [4]. In
affected individuals, proteinuria was detected between age
2 months and 9 years; renal histology included diffuse
mesangial sclerosis and FSGS. Response to treatment
included steroid resistance and complete remission to either
steroids or cyclosporine. This is the first time a genetic
podoctye disease has been associated with steroid-sensitive
nephrotic syndrome [4].
Syndromic FSGS
The above genes have mutations associated with FSGS in
the absence of extrarenal manifestations. To date, at least
five genes have been associated with syndromes of which
FSGS is often a part.
WT1
The product of the Wilm’s tumor gene (WT1) is required for
normal development of the genitourinary system and
mesothelial tissues and is overexpressed in leukemia and
various types of solid tumors. WT1 mutations have been
identified in patients with Wilm’s tumor, WAGR syndrome
(Wilm’s tumor, aniridia, genitourinary abnormalities, and
retardation-hypospadias and bilateral cryptorchidism may
be seen), Denys-Drash syndrome (urogenital abnormalities,
renal failure, pseudohermaphroditism, and Wilm’s tumor),
Frasier syndrome (male pseudohermaphroditism and pro-
gressive glomerulopathy), and isolated diffuse mesangial
sclerosis. WT1 has four major RNA splice variants, and the
interactions between the four polypeptide products may
play a role in the control of cellular proliferation and
differentiation. WT1 acts as either a transcriptional activator
or repressor, depending on chromosomal and cellular
context. WT1 is expressed predominantly in the kidney
and certain hematopoietic cells [38].
The Wilm’s tumor upstream neighbor (WIT1) is located
upstream of WT1, localized to chromosome 11p13. WIT1 is
transcribed in the opposite direction of WT1, and some
WIT1 splice variants include antisense portions of WT1.
WIT1 transcripts may play a role in transcriptional
regulation of WT1 [39]. WIT1 protein contains 92 amino
acids and is expressed in fetal kidney and spleen [40].
Single nucleotide polymorphisms (SNPs) in both WT1 and
WIT1 and their common promoter (rs6508, rs2301254, and
rs1799937) were significantly associated with HIV-sero-
negative FSGS, suggesting that variants in these genes may
mediate pathogenesis by altering WT1 function [41].
LMX1B
The nail–patella syndrome includes various combinations
of dystrophic nails, absent or malformed patellas, elbow
contractures, glaucoma, and FSGS [42]. The gene respon-
sible, LMX1B, is a transcription factor required for
expression of CD2AP and NPHS2, among other genes [43].
tRNA
Leu
Mutations in the mitochondrial gene encoding tRNA
Leu are
associated with the MELAS syndrome (myopathy, enceph-
alopathy, lactic acidosis, and stroke-like episodes), typically
presenting in infancy or early childhood. There is a
maternal inheritance pattern, and the most common
mutation is A324G [44, 45]. Patients with this mutation
may also present later in childhood or in adulthood with
FSGS associated with deafness or diabetes mellitus, or
occasionally with sporadic FSGS.
COQ2
Another mitochondriopathy associated with FSGS has been
described recently. A mutation in COQ2, encoding an
enzyme required for synthesis of coenzyme Q10 (ubiqui-
none), which is present in all membranes. A COQ2
m u t a t i o nw a sf o u n di na ni n f a n tw h op r e s e n t e da t
12 months of age with psychomotor delay, optic atrophy,
and FSGS [46].
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An infant with epidermolysis bullosa, pyloric atresia, and
FSGS was found to have a homozygous missense mutation
(R1281W) in β4 integrin. The α6β4 integrin binds laminin-
5 (a trimer composed of the laminin α5, β3, and γ3 chains).
Although the major podocyte integrin is α3β1, the authors
showed that podocytes do express low levels of α6β4.
Whereas other families with α6β4 integrin mutations and
epidermolysis bullosa have been reported, to date, only the
one case of FSGS has been reported [47].
Summary
The recent advances in understanding the pathophysiology of
FSGS and molecular function of glomerular filtration barrier
come in large part from genetic linkage and positional cloning
studies. Because a substantial percentage (up to 30%) of
sporadic, steroid-resistant nephrotic syndrome patients carry
the specific genetic mutation causally linked to FSGS, it may
be advisable that all patients who have failed steroids should
be offered genetic screening for mutations at the time of or
prior to starting more aggressive treatments, as those patients
have been shown to unfavorably respond to immunosuppres-
sant therapy [18]. Genetic testing could be performed in
several research laboratories and now is also being offered by
a commercial laboratory. Genetic testing for familial forms of
FSGS might also be clinically informative in situations
where living-related donor transplant is considered.
The exact role and function of the newly discovered
genes and proteins are being investigated by in vitro and in
vivo mechanistic studies. Those genes and proteins inter-
actions seem to change susceptibility to kidney disease
progression. Better understanding of their exact role in the
development of FSGS may influence future therapies and
outcomes in this complex disease.
Questions
(Answers appear following the reference list)
1. Familial form of FSGS is most commonly associated
with mutation of:
a) NPHS1 (gene encoding nephrin)
b) WT1 (gene encoding Wilm’s tumor protein)
c) CD2AP (gene encoding CD2-associated protein)
d) NPHS2 (gene encoding podocin)
2. Mutation of which gene is likely associated with
steroid-sensitive nephrotic syndrome:
a) NPHS1
b) NPHS2
c) TRPC6
d) None of the above
3. Although established as a cause and model of FSGS in
animals, mutation of which gene is only rarely found in
humans:
a) NPHS1
b) NPHS2
c) CD2AP
d) TRPC6
4. Proteins that interact with each other in the vicinity of
the slit diaphragm are:
a) Nephrin, WT1, TRPC6
b) Nephrin, Alpha-actinin-4, Podocin
c) Podocin, CD2AP, Nephrin
d) Nephrin, CD2AP, Alpha-actinin-4
5. FSGS that is associated with hypospadias and bilateral
cryptorchidism may result from the mutation of:
a) NPHS2
b) WT1
c) CD2AP
d) TRPC6
References
1. Churg J, Habib R, White RHR (1970) The pathology of the
nephrotic syndrome in children. A report of the International
Study of Kidney Disease in Children. Lancet 1:1299–1302
2. Klahr S, Morrissey J (2003) Progression of chronic renal disease.
Am J Kidney Dis 41:S3–S7
3. Caulfield JP, Farquhar MG (1974) The permeability of glomer-
ular capillaries to graded dextrans. Identification of the basement
membrane as the primary filtration barrier. J Cell Biol 63:883–
903
4. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D,
Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S,
Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD,
Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich
A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M,
Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD,
Katan M, Liu J, Attanasio M, O’toole JF, Hasselbacher K, Mucha
B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV,
Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006)
Positional cloning uncovers mutations in PLCE1 responsible for a
nephrotic syndrome variant that may be reversible. Nat Genet
38:1397–1405
5. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P,
Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R,
Kashtan CE, Peltonen L, Holmberg C, Olsen A, Tryggvason K
(1998) Positionally cloned gene for a novel glomerular protein–
nephrin–is mutated in congenital nephrotic syndrome. Mol Cell
1:575–582
6. Koziell A, Grech V, Hussain S, Lee G, Lenkkeri U, Tryggvason
K, Scambler P (2002) Genotype/phenotype correlations of NPHS1
642 Pediatr Nephrol (2007) 22:638–644and NPHS2 mutations in nephrotic syndrome advocate a
functional inter-relationship in glomerular filtration. Hum Mol
Genet 11:379–388
7. Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Makela E,
Sandin S, Ruotsalainen V, Cheng RH, Jalanko H, Skoglund U,
Tryggvason K (2004) Nephrin strands contribute to a porous slit
diaphragm scaffold as revealed by electron tomography. J Clin
Invest 114:1475–1483
8. Jones N, Blasutig IM, Eremina V, Ruston JM, Bladt F, Li H,
Huang H, Larose L, Li SSC, Takano T, Quaggin, SE, Pawson T
(2006) Nck adaptor proteins link nephrin to the actin cytoskeleton
of kidney podocytes. Nature 440:818–823
9. Beltcheva O, Martin P, Lenkkeri U, Tryggvason K (2001)
Mutation spectrum in the nephrin gene (NPHS1) in congenital
nephrotic syndrome. Hum Mutat 17:368–373
10. Bolk S, Puffenberger EG, Hudson J, Morton DH, Chakravarti A
(1999) Elevated frequency and allelic heterogeneity of congenital
nephrotic syndrome, Finnish type, in the Old Order Mennonites.
Am J Hum Genet 65:1785–1790
11. Aya K, Tanaka H, Seino Y (2000) Novel mutation in the nephrin
gene of a Japanese patient with congenital nephrotic syndrome of
the Finnish type. Kidney Int 57:401–404
12. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber
A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2,
encoding the glomerular protein podocin, is mutated in autosomal
recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–
354
13. Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W,
Shaw AS, Holzman LB, Mundel P (2001) Podocin, a raft-
associated component of the glomerular slit diaphragm, interacts
with CD2AP and nephrin. J Clin Invest 108:1621–1629
14. Huber TB, Simons M, Hartleben B, Sernetz L, Schmidts M,
Gundlach E, Saleem MA, Walz G, Benzing T (2003) Molecular
basis of the functional podocin-nephrin complex: mutations in the
NPHS2 gene disrupt nephrin targeting to lipid raft microdomains.
Hum Mol Genet 12:3397–3405
15. Roselli S, Heidet L, Sich M, Henger A, Kretzler M, Gubler MC,
AntignacC (2004) Early glomerularfiltrationdefect andsevere renal
disease in podocin-deficient mice. Mol Cell Biol 24:550–560
16. Caridi G, Bertelli R, Carrea A, Di Duca M, Catarsi P, Artero M,
Carraro M, Zennaro C, Candiano G, Musante L, Seri M, Ginevri
F, Perfumo F, Ghiggeri GM (2001) Prevalence, genetics, and
clinical features of patients carrying podocin mutations in steroid-
resistant nonfamilial focal segmental glomerulosclerosis. J Am
Soc Nephrol 12:2742–2746
17. Tsukaguchi H, Sudhakar A, Le TC, Nguyen T, Yao J, Schwimmer
JA, Schachter AD, Poch E, Abreu PF, Appel GB, Pereira AB,
Kalluri R, Pollak MR (2002) NPHS2 mutations in late-onset focal
segmental glomerulosclerosis: R229Q is a common disease-
associated allele. J Clin Invest 110:1659–1666
18. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE,
Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A,
Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F,
Arbeitsgemeinschaft Fur Padiatrische Nephrologie Study Group
(2004) Patients with mutations in NPHS2 (podocin) do not
respond to standard steroid treatment of nephrotic syndrome. J
Am Soc Nephrol 15:722–732
19. Aucella F, De Bonis P, Gatta G, Muscarella LA, Vigilante M,
di Giorgio G, D’Errico M, Zelante L, Stallone C, Bisceglia L
(2005) Molecular analysis of NPHS2 and ACTN4 genes in a
series of 33 Italian patients affected by adult-onset nonfamilial
focal segmental glomerulosclerosis. Nephron Clin Pract 99:
c31–c36
20. Monteiro EJ, Pereira AC, Pereira AB, Krieger JE, Mastroianni-
Kirsztajn G (2006) NPHS2 mutations in adult patients with primary
focal segmental glomerulosclerosis. J Nephrol 19:366–371
21. Maruyama K, Iijima K, Ikeda M, Kitamura A, Tsukaguchi H,
Yoshiya K, Hoshii S, Wada N, Uemura O, Satomura K, Honda M,
Yoshikawa N (2003) NPHS2 mutations in sporadic steroid-
resistant nephrotic syndrome in Japanese children. Pediatr
Nephrol 18:412–416
22. Weber S,GribouvalO,EsquivelEL,MoriniereV,TeteMJ,Legendre
C, Niaudet P, Antignac C (2004) NPHS2 mutation analysis shows
genetic heterogeneity of steroid-resistant nephrotic syndrome and
low post-transplant recurrence. Kidney Int 66:571–579
23. Franceschini N, North KE, Kopp JB, McKenzie L, Winkler C
(2006) NPHS2 gene, nephrotic syndrome and focal segmental
glomerulosclerosis: a HuGE review. Genet Med 8:63–75
24. Pereira AC, Pereira AB, Mota GF, Cunha RS, Herkenhoff FL,
Pollak MR, Mill JG, Krieger JE (2004) NPHS2 R229Q functional
variant is associated with microalbuminuria in the general
population. Kidney Int 65:1026–1030
25. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O,
Miner JH, Shaw AS (1999) Congenital nephrotic syndrome in
mice lacking CD2-associated protein. Science 286:312–315
26. Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH,
Unanue ER, Shaw AS (2003) CD2-associated protein haploinsuf-
ficiency is linked to glomerular disease susceptibility. Science
300:1298–1300
27. Kirsch KH, Georgescu MM, Ishimaru S, Hanafusa H (1999)
CMS: an adapter molecule involved in cytoskeletal rearrange-
ments. Proc Nat Acad Sci USA 96:6211–6216
28. Huber TB, Kwoh C, Wu H, Asanuma K, Godel M, Hartleben B,
Blumer KJ, Miner JH, Mundel P, Shaw AS (2006) Bigenic mouse
models of focal segmental glomerulosclerosis involving pairwise
interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest
116:1337–1345
29. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong
H-Q, Mathis BJ, Rodriguez-Perez J-C, Allen PG, Beggs AH,
Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-
4, cause familial focal segmental glomerulosclerosis. Nat Genet
24:251–256
30. Weins A, Kenlan P, Herbert S, Le TC, Villegas I, Kaplan BS,
Appel GB, Pollak MR (2005) Mutational and Biological Analysis
of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am
Soc Nephrol 16:3694–3701
31. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, Yamada
Y, Chiba H, Hirohashi S (1998) Actinin-4, a novel actin-bundling
protein associated with cell motility and cancer invasion. J Cell
Biol 140:1383–1393
32. Patrie KM, Drescher AJ, Welihinda A, Mundel P, Margolis B
(2002) Interaction of two actin-binding proteins, synaptopodin
and alpha-actinin-4, with the tight junction protein MAGI-1. J
Biol Chem 277:30183–30190
33. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H,
Kalluri R, Gerszten RE, Pollak MR (2003) Mice deficient in
alpha-actinin-4 have severe glomerular disease. J Clin Invest
111:1683–1690
34. Dandapani SV, Sugimoto H, Matthews BD, Kolb RJ, Sinha S,
Gerszten RE, Zhou J, Ingber DE, Kalluri R, Pollak MR (2007)
Alpha -actinin-4 is required for normal podocyte adhesion. J Biol
Chem 282:467–477
35. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann
T, Schultz G (1999) Direct activation of human TRPC6 and
TRPC3 channels by diacylglycerol. Nature 397:259–263
36. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, Faul
C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H,
Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR
(2005) TRPC6 is a glomerular slit diaphragm-associated channel
required for normal renal function. Nat Genet 37:739–744
37. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T,
Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette
Pediatr Nephrol (2007) 22:638–644 643JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB
(2005) A mutation in the TRPC6 cation channel causes familial
focal segmental glomerulosclerosis. Science 308:1801–1804
38. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP
(1990)HomozygousdeletioninWilmstumoursofazinc-fingergene
identified by chromosome jumping. Nature 343:774–778
39. Campbell CE, Huang A, Gurney AL, Kessler PM, Hewitt JA,
Williams BRG (1994) Antisense transcripts and protein binding
motifs within the Wilms tumour (WT1) locus. Oncogene 9:583–595
40. Huang A, Campbell CE, Bonetta L, McAndrews-Hill MS,
Chilton-MacNeill S, Coppes MJ, Law DJ, Feinberg AP, Yeger
H, Williams BRG (1990) Tissue, developmental, and tumor-
specific expression of divergent transcripts in Wilms tumor.
Science 250:991–994
41. Orloff MS, Iyengar SK, Winkler CA, Goddard KA, Dart RA,
Ahuja TS, Mokrzycki M, Briggs WA, Korbet SM, Kimmel PL,
Simon EE, Trachtman H, Vlahov D, Michel DM, Berns JS, Smith
MC, Schelling JR, Sedor JR, Kopp JB (2005) Variants in the
Wilms’ tumor gene are associated with focal segmental glomer-
ulosclerosis in the African American population. Physiol
Genomics 21:212–221
42. Bongers EM, Gubler MC, Knoers NV (2002) Nail-patella
syndrome. Overview on clinical and molecular findings. Pediatr
Nephrol 17:703–712
43. Miner JH, Morello R, Andrews KL, Li C, Antignac C, Shaw AS,
Lee B (2002) Transcriptional induction of slit diaphragm genes by
Lmx1b is required in podocyte differentiation. J Clin Invest
109:1065–1072
44. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A,
Taguma Y (2001) Clinical and pathologic features of focal
segmental glomerulosclerosis with mitochondrial tRNALeu
(UUR) gene mutation. Kidney Int 59:1236–1243
45. Guery B, Choukroun G, Noel LH, Clavel P, Rotig A, Lebon S,
Rustin P, Bellane-Chantelot C, Mougenot B, Grunfeld JP,
Chauveau D (2003) The spectrum of systemic involvement in
adults presenting with renal lesion and mitochondrial tRNA(Leu)
gene mutation. J Am Soc Nephrol 14:2099–2108
46. Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, Dimauro S,
Hirano M (2006) A Mutation in Para-Hydroxybenzoate-Poly-
prenyl Transferase (COQ2) Causes Primary Coenzyme Q10
Deficiency. Am J Hum Genet 78:345–349
47. Pulkkinen L, Rouan F, Bruckner-Tuderman L, Wallerstein R,
Garzon M, Brown T, Smith L, Carter W, Uitto J (1998) Novel
ITGB4 mutations in lethal and nonlethal variants of epidermolysis
bullosa with pyloric atresia: missense versus nonsense. Am J Hum
Genet 63:1376–1387
Answers
1: D
2: D
3: C
4: C
5: B
644 Pediatr Nephrol (2007) 22:638–644